Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rVSV∆G-LASV-GPC vaccine for Lassa fever in healthy adults
NCT04794218Phase 1Active, not recruiting
- Sponsor
- International AIDS Vaccine Initiative
- Start
- Jun 2021
- Primary completion
- Dec 2023
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of rVSV∆G-LASV-GPC in Lassa fever, sponsored by International AIDS Vaccine Initiative. Started Jun 2021; status: active, not recruiting.
02
Drugs
rVSV∆G-LASV-GPC
03
Conditions
Lassa fever
Beyond the preview
Go deeper on NCT04794218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04794218.